Description
- Probiotic for Women with 30+ Years of Clinical Research
- Supports Vaginal and Urinary Tract Health*
- Shelf-Stable Version of Fem-Dophilus: No Refrigeration Necessary
- Clinically-Documented Benefits
- More Than 20 Studies Demonstrating Safety and Efficacy
- With 2 patented strains: Lacticaseibacillus rhamnosus GR-1® and Limosilactobacillus reuteri RC-14®. These beneficial strains populate the vaginal tract with healthy bacteria to balance the vaginal microbiome and help maintain a healthy vaginal and urinary tract.* These two strains are the most clinically published strains for vaginal health worldwide**, and were carefully selected due to their effectiveness in these studies.* A special manufacturing process protects the probiotic strains in Fem-Dophilus® from stomach acid, enhances probiotic bacterial survival to the lower intestine, and into the vaginal tract.*
- Package contains a smaller, Activ-Vial™ moisture-controlled desiccant bottle for better stability of probiotic bacteria
- In one randomized clinical trial, 60% of women studied had healthy vaginal flora after 28 days of use at 0.8 billion CFU per day of a probiotic (formulated with L. rhamnosus, GR-1® and L. reuteri, RC-14®) compared to 40% before supplementation. Whereas in the control group (taking 10 billion CFU of common strain, L. rhamnosus GG) there was no improvement in the percentage of women with healthy vaginal flora.¹
- GR-1 and RC-14 are trademarks of Chr. Hansen A/S.
- Made in Denmark by Chr. Hansen A/S
- **As of 8/1/2022
- ¹Reid et al. (2001). FEMS Immunol. Med. Microbiol.
Reviews
There are no reviews yet.